Posted by Michael Wonder on 03 Dec 2024
Shorla Oncology announces FDA approval of Imkeldi (imatinib) oral solution, an oral liquid for the treatment of certain forms of leukaemia and other cancers
25 November 2024 - Imkeldi marks Shorla Oncology’s fourth FDA Approval.
Shorla Oncology announced today that the FDA has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukaemia and other cancers.
